Full Press Release Details
COMPANY 39 ANNUAL HEALTHCARE CONFERENCE BOSTON, MA MARCH 2019Exhibit 99.1 UNUM THERAPEUTICS CORPORATE PRESENTATION TH COWEN AND COMPANY 39 ANNUAL HEALTHCARE CONFERENCE BOSTON, MA MARCH 2019
FORWARD-LOOKING STATEMENTS AND RISK FACTORS This presentation and the
accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those
expressed or implied by such forward looking statements. All statements other than statements of historical fact could be deemed forward-looking, including, but not limited to, any statements of the plans, strategies, and objectives of management
for future operations, including our clinical development and commercialization plans; any projections of financial information; any statement about historical results that may suggest trends for our business; any statement of expectation or belief
regarding future events; potential markets or market size, technology developments, our clinical product pipeline, clinical data or the implications thereof, enforceability of our intellectual property rights, competitive strengths or our position
within the industry; any statements regarding the anticipated benefits of our collaborations or other strategic transactions; and any statements of assumptions underlying any of the items mentioned. These statement are based on estimates and
information available to us at the time of this presentation and are not guarantees of future performance. Actual results could differ materially from our current expectations as a result of many risks and uncertainties, including but not limited
to, risks associated with: the success, cost and timing of our product development activities and clinical trials; our ability to obtain regulatory approval for and to commercialize our product candidates; our ability to establish a
commercially-viable manufacturing process and manufacturing infrastructure; regulatory requirements and regulatory developments; the effects of competition and technological advances; our dependence on third-party collaborators and other contractors
in our research and development activities, including for the conduct of clinical trials and the manufacture of our product candidates; our ability to obtain, maintain, or protect intellectual property rights related to our product candidates; among
others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see our periodic filings filed
from time to time with the Securities and Exchange Commission. Unless as required by law, we assume no obligation and do not intend to update these forward looking statements or to conform these statements to actual results or to changes in our
expectations. All of Unum Therapeutics ("Unum") product candidates are investigational product candidates and their safety and efficacy have not yet been established. Unum has not obtained marketing approval for any product, and there is
no certainty that any marketing approvals will be obtained or as to the timelines on which they will be obtained. Any data pertaining to Unum product candidates is interim data, and may include investigator-reported interim data for which Unum has
not yet independently reviewed the source data. The interim data may not be representative of the final results that may be obtained in the corresponding trials and results from earlier trials may not be representative of results obtained in later
trial or pivotal trials. PAGE 2FORWARD-LOOKING STATEMENTS AND RISK FACTORS This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties
ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward looking statements. All statements other than statements of historical fact could be deemed forward-looking,
including, but not limited to, any statements of the plans, strategies, and objectives of management for future operations, including our clinical development and commercialization plans; any projections of financial information; any statement about
historical results that may suggest trends for our business; any statement of expectation or belief regarding future events; potential markets or market size, technology developments, our clinical product pipeline, clinical data or the implications
thereof, enforceability of our intellectual property rights, competitive strengths or our position within the industry; any statements regarding the anticipated benefits of our collaborations or other strategic transactions; and any statements of
assumptions underlying any of the items mentioned. These statement are based on estimates and information available to us at the time of this presentation and are not guarantees of future performance. Actual results could differ materially from our
current expectations as a result of many risks and uncertainties, including but not limited to, risks associated with: the success, cost and timing of our product development activities and clinical trials; our ability to obtain regulatory approval
for and to commercialize our product candidates; our ability to establish a commercially-viable manufacturing process and manufacturing infrastructure; regulatory requirements and regulatory developments; the effects of competition and technological
advances; our dependence on third-party collaborators and other contractors in our research and development activities, including for the conduct of clinical trials and the manufacture of our product candidates; our ability to obtain, maintain, or
protect intellectual property rights related to our product candidates; among others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as
well as risks relating to our business in general, see our periodic filings filed from time to time with the Securities and Exchange Commission. Unless as required by law, we assume no obligation and do not intend to update these forward looking
statements or to conform these statements to actual results or to changes in our expectations. All of Unum Therapeutics ("Unum") product candidates are investigational product candidates and their safety and efficacy have not yet been
established. Unum has not obtained marketing approval for any product, and there is no certainty that any marketing approvals will be obtained or as to the timelines on which they will be obtained. Any data pertaining to Unum product candidates is
interim data, and may include investigator-reported interim data for which Unum has not yet independently reviewed the source data. The interim data may not be representative of the final results that may be obtained in the corresponding trials and
results from earlier trials may not be representative of results obtained in later trial or pivotal trials. PAGE 2
KEY COMPANY HIGHLIGHTS Providing potentially curative T cell therapies
to treat a broad range of cancer patients NOVEL TECHNOLOGIES to overcome limitations of current T cell therapies 1 Potent ANTI-TUMOR ACTIVITY and ENCOURAGING SAFETY in lead program 2 Ability to address challenges in treating SOLID TUMORS 3 MULTIPLE
MILESTONES with readouts from four clinical trials in 2019 4 PAGE 3KEY COMPANY HIGHLIGHTS Providing potentially curative T cell therapies to treat a broad range of cancer patients NOVEL TECHNOLOGIES to overcome limitations of current T cell
therapies 1 Potent ANTI-TUMOR ACTIVITY and ENCOURAGING SAFETY in lead program 2 Ability to address challenges in treating SOLID TUMORS 3 MULTIPLE MILESTONES with readouts from four clinical trials in 2019 4 PAGE 3
CURRENT CHALLENGES FOR T CELL THERAPIES CAR-T therapy liabilities limit
their use in broad patient populations n CRS and/or neurotoxicity are observed in the majority of patients who are treated Severe toxicities with currently approved CAR-T therapies, and can be severe or life-threatening associated with n These
toxicities limit the patient population fit for CAR-T therapy, create T cell activation unpredictable risks to patients and unnecessary burden on the healthcare system n Traditional CAR-T cannot discriminate between high level expression of antigen
on Limited ability to tumor cells versus low level expression on healthy tissue target solid tumor n Several CAR-Ts have shown toxicities consistent with on-target - off-tumor toxicity antigens (e.g., CAIX, HER2) n The microenvironments of
many solid tumors inhibit immune function limiting Lack of efficacy in efficacy of engineered T cells solid tumors due to n CAR-T therapies to date have not demonstrated potent efficacy in solid tumors immunosuppression PAGE 4CURRENT CHALLENGES FOR
T CELL THERAPIES CAR-T therapy liabilities limit their use in broad patient populations n CRS and/or neurotoxicity are observed in the majority of patients who are treated Severe toxicities with currently approved CAR-T therapies, and can be severe
or life-threatening associated with n These toxicities limit the patient population fit for CAR-T therapy, create T cell activation unpredictable risks to patients and unnecessary burden on the healthcare system n Traditional CAR-T cannot
discriminate between high level expression of antigen on Limited ability to tumor cells versus low level expression on healthy tissue target solid tumor n Several CAR-Ts have shown toxicities consistent with on-target - off-tumor toxicity
antigens (e.g., CAIX, HER2) n The microenvironments of many solid tumors inhibit immune function limiting Lack of efficacy in efficacy of engineered T cells solid tumors due to n CAR-T therapies to date have not demonstrated potent efficacy in solid
tumors immunosuppression PAGE 4
ACTR: ANTIBODY-COUPLED T CELL RECEPTOR An engineered T cell receptor
that uses tumor-targeting mAbs to direct attack Potential ACTR benefits tumor-specific antibody The same universal T cell product can be ACTR antigen used in several different cancer indications n Potent anti-tumor activity with reduced rates
and severities of CAR-T associated toxicities n Ability to pursue antigens inaccessible to CAR-T n Selectively target solid tumor antigens, avoiding on-target off-tumor toxicity ACTR T cell tumor cell n Target T cell-expressed antigens, avoiding
fratricide ACTR components antibody recognition: ectodomain of CD16 (normally found on NK cells), linked via a hinge and transmembrane domain T cell activation: costimulatory signals (e.g., CD28 or 41BB) and TCR signals (CD3!) PAGE
5ACTR: ANTIBODY-COUPLED T CELL RECEPTOR An engineered T cell receptor that uses tumor-targeting mAbs to direct attack Potential ACTR benefits tumor-specific antibody The same universal T cell product can be ACTR antigen used in several
different cancer indications n Potent anti-tumor activity with reduced rates and severities of CAR-T associated toxicities n Ability to pursue antigens inaccessible to CAR-T n Selectively target solid tumor antigens, avoiding on-target off-tumor
toxicity ACTR T cell tumor cell n Target T cell-expressed antigens, avoiding fratricide ACTR components antibody recognition: ectodomain of CD16 (normally found on NK cells), linked via a hinge and transmembrane domain T cell
activation: costimulatory signals (e.g., CD28 or 41BB) and TCR signals (CD3!) PAGE 5
BOXR: BOLT-ON CHIMERIC RECEPTOR Designed to improve T cell function in
solid tumor microenvironments Potential BOXR benefits chimeric receptor bolt-on' (ACTR or CAR) transgene T cell function improved by expression of a immunosuppressive cells bolt-on' transgene (e.g., metabolic (Treg,
MDSC) enzymes/transporters, signaling receptors/ligands, survival factors, etc.) BOXR T cell Counteracts mechanisms driving secreted factors immunosuppression in solid tumors metabolites Metabolic competition Immune cell
suppression (T-Reg, MDSC) Chronic antigen stimulation tumor cells Bolt-on transgene may augment many types BOXR components of T cell therapies (ACTR, CAR, TCR, TIL, etc.) chimeric receptor: universal ACTR or antigen-specific CAR
drives cancer cell targeting and attack bolt-on: novel transgene re-programs T cell biology to improve functionality in the tumor microenvironment PAGE 6BOXR: BOLT-ON CHIMERIC RECEPTOR Designed to improve T cell function in solid tumor
microenvironments Potential BOXR benefits chimeric receptor bolt-on' (ACTR or CAR) transgene T cell function improved by expression of a immunosuppressive cells bolt-on' transgene (e.g., metabolic (Treg, MDSC)
enzymes/transporters, signaling receptors/ligands, survival factors, etc.) BOXR T cell Counteracts mechanisms driving secreted factors immunosuppression in solid tumors metabolites Metabolic competition Immune cell suppression
(T-Reg, MDSC) Chronic antigen stimulation tumor cells Bolt-on transgene may augment many types BOXR components of T cell therapies (ACTR, CAR, TCR, TIL, etc.) chimeric receptor: universal ACTR or antigen-specific CAR drives
cancer cell targeting and attack bolt-on: novel transgene re-programs T cell biology to improve functionality in the tumor microenvironment PAGE 6
PIPELINE Rapidly expanding pipeline in both hematologic and solid tumor
cancers Product Candidate Indication Antibody Pre-Clinical Phase I Hematologic Cancers ACTR707 r/r CD20+ B cell NHL rituximab ATTCK-20-03 ACTR087 r/r CD20+ B cell NHL rituximab ATTCK-20-2 SEA-BCMA ACTR087 r/r Multiple Myeloma ATTCK-17-01 with
Seattle Genetics Solid Tumor Cancers ACTR707 Advanced HER2+ cancers trastuzumab ATTCK-34-01 BOXR1030 Advanced GPC3+ cancers n/a ACTR087 and ACTR707 distinguished by differences in co-stimulatory domains (ACTR087: 4-1BB, ACTR707: CD28) and structural
sequences PAGE 7PIPELINE Rapidly expanding pipeline in both hematologic and solid tumor cancers Product Candidate Indication Antibody Pre-Clinical Phase I Hematologic Cancers ACTR707 r/r CD20+ B cell NHL rituximab ATTCK-20-03 ACTR087 r/r CD20+ B
cell NHL rituximab ATTCK-20-2 SEA-BCMA ACTR087 r/r Multiple Myeloma ATTCK-17-01 with Seattle Genetics Solid Tumor Cancers ACTR707 Advanced HER2+ cancers trastuzumab ATTCK-34-01 BOXR1030 Advanced GPC3+ cancers n/a ACTR087 and ACTR707 distinguished by
differences in co-stimulatory domains (ACTR087: 4-1BB, ACTR707: CD28) and structural sequences PAGE 7
HEMATOLOGIC CANCERSHEMATOLOGIC CANCERS
ACTR IN LYMPHOMA Provides proof-of-platform for the ACTR technology,
demonstrating potential best-in-class product profile Compelling profile demonstrated at early dose levels in two independent trials in r/r NHL ATTCK-20-03: ACTR707 (CD28) (selected as program lead) ATTCK-20-2: ACTR087 (41BB)
Anti-tumor activity comparable to approved NHL CAR-T therapies Favorable safety demonstrated at the correct dose level Potential profile opens path for applying T cell therapies across broad NHL patient populations including
those unfit for current CAR-T PAGE 9ACTR IN LYMPHOMA Provides proof-of-platform for the ACTR technology, demonstrating potential best-in-class product profile Compelling profile demonstrated at early dose levels in two independent trials in
r/r NHL ATTCK-20-03: ACTR707 (CD28) (selected as program lead) ATTCK-20-2: ACTR087 (41BB) Anti-tumor activity comparable to approved NHL CAR-T therapies Favorable safety demonstrated at the correct dose level
Potential profile opens path for applying T cell therapies across broad NHL patient populations including those unfit for current CAR-T PAGE 9
TESTING ACTR707 IN NHL Study Design and Objectives Phase I,
single arm trial testing escalating single doses of ACTR+ T cells in combination with rituximab Patients pretreated with 3 days of lymphodepleting chemotherapy (fludarabine + cytarabine) 2 Rituximab administered on the R-CHOP schedule
(375 mg/m IV every 3-weeks) Key Eligibility: Rituximab-treated CD20+ aggressive NHL; Primary refractory, >2 prior lines of therapy, or post auto-HSCT Primary objective is safety, determination of MTD and proposed recommended Phase
II dose Status ATTCK-20-03 Trial Design 14 patients dosed to date through first three dose cohorts Dose Escalation* Cleared DLT assessment at DL3, Expansion completing response assessments Enrolling patients at DL4 Cohort 1, n =
6 Cohort 2, n = 3 Cohort 3, n = 5 Cohort 4, n = 3-6 n = 26 Next Steps 25M Cells 40M Cells 55M Cells RP2D (TBD) 80M Cells Complete dose escalation, safety evaluation and response assessments currently enrolling Cohort expansion at
recommended phase 2 dose (RP2D) *study design allows for additional dose cohorts PAGE 10TESTING ACTR707 IN NHL Study Design and Objectives Phase I, single arm trial testing escalating single doses of ACTR+ T cells in combination with
rituximab Patients pretreated with 3 days of lymphodepleting chemotherapy (fludarabine + cytarabine) 2 Rituximab administered on the R-CHOP schedule (375 mg/m IV every 3-weeks) Key Eligibility: Rituximab-treated CD20+ aggressive
NHL; Primary refractory, >2 prior lines of therapy, or post auto-HSCT Primary objective is safety, determination of MTD and proposed recommended Phase II dose Status ATTCK-20-03 Trial Design 14 patients dosed to date through first
three dose cohorts Dose Escalation* Cleared DLT assessment at DL3, Expansion completing response assessments Enrolling patients at DL4 Cohort 1, n = 6 Cohort 2, n = 3 Cohort 3, n = 5 Cohort 4, n = 3-6 n = 26 Next Steps 25M Cells 40M
Cells 55M Cells RP2D (TBD) 80M Cells Complete dose escalation, safety evaluation and response assessments currently enrolling Cohort expansion at recommended phase 2 dose (RP2D) *study design allows for additional dose cohorts PAGE
ACTR707 TOLERABILITY IN NHL No DLTs and no significant CRS or
neurologic events in the first two dose levels Subjects with Serious Adverse Events (SAEs) Related to ACTR707 Preferred Term, n (%) Dose Level 1 (n=6) Dose Level 2 (n=3) Febrile neutropenia 1 (17) 1 (33) Pancytopenia 0 (0) 1 (33) Subjects with AESI,
n Adverse Events of Special Interest (AESI) Dose Level 1 Dose Level 2 (n=6) (n=3) New malignancy 0 0 Cytokine release syndrome 0 0 Use of therapeutic plasma exchange for any non-disease related AE 0 0 Clinically significant neurologic disorder 0 0
Clinically significant rheumatologic/autoimmune disorder 0 0 Clinically significant hematologic disorder (excluding cytopenias related to LD chemo) 0 0 Clinically significant = in the opinion of the investigator, clinically meaningful Database
snapshot: 01November18 PAGE 11ACTR707 TOLERABILITY IN NHL No DLTs and no significant CRS or neurologic events in the first two dose levels Subjects with Serious Adverse Events (SAEs) Related to ACTR707 Preferred Term, n (%) Dose Level 1 (n=6) Dose
Level 2 (n=3) Febrile neutropenia 1 (17) 1 (33) Pancytopenia 0 (0) 1 (33) Subjects with AESI, n Adverse Events of Special Interest (AESI) Dose Level 1 Dose Level 2 (n=6) (n=3) New malignancy 0 0 Cytokine release syndrome 0 0 Use of therapeutic
plasma exchange for any non-disease related AE 0 0 Clinically significant neurologic disorder 0 0 Clinically significant rheumatologic/autoimmune disorder 0 0 Clinically significant hematologic disorder (excluding cytopenias related to LD chemo) 0 0
Clinically significant = in the opinion of the investigator, clinically meaningful Database snapshot: 01November18 PAGE 11
ACTR707 ANTI-TUMOR ACTIVITY IN NHL Potent antitumor activity including
complete responses in initial cohorts Dose Level 1 Six enrolled and treated subjects Three subjects with complete responses; three with disease progression Dose Level 2 Three enrolled and treated subjects One subject with
complete response; two with disease progression Summary of complete responses # prior Refractory* to Dose Level Response Diagnosis therapies^ prior therapy 1 Complete 2 no Gr3b FL 1 Complete 5 yes DLBCL Baseline Cycle 3 1 Complete 3 yes DLBCL
Representative image of complete response in DLBCL subject treated with 5 prior therapies including ASCT 2 Complete 3 yes DLBCL *Refractory defined as PD as best response to any line of prior therapy or relapse 12 months post ASCT ^All
subjects received rituximab as prior therapy Database snapshot: 01November18 PAGE 12ACTR707 ANTI-TUMOR ACTIVITY IN NHL Potent antitumor activity including complete responses in initial cohorts Dose Level 1 Six enrolled and treated subjects
Three subjects with complete responses; three with disease progression Dose Level 2 Three enrolled and treated subjects One subject with complete response; two with disease progression Summary of complete responses # prior
Refractory* to Dose Level Response Diagnosis therapies^ prior therapy 1 Complete 2 no Gr3b FL 1 Complete 5 yes DLBCL Baseline Cycle 3 1 Complete 3 yes DLBCL Representative image of complete response in DLBCL subject treated with 5 prior therapies